a strong trendp = 0.063
Following adjustment for performance status, PCI score, and histopathologic subtype, a strong trend towards longer PFS was observed for individuals with tumors sensitive to mitomycin C and cisplatin ( p = 0.063 and 0.062, respectively; Table 3 ).